Treatment and referral patterns for psoriasis in United Kingdom primary care: A retrospective cohort study

BMC Dermatology

Volumn 13, Issue , 2013, Pages

  Khalid, Javaria Mona ^a   Globe, Gary ^b   Fox, Kathleen M ^c   Chau, Dina ^b   Maguire, Andrew ^a   Chiou, Chio Fang ^d  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b AMGEN INC   (United States)

^c Strategic Healthcare Solutions LLC   (United States)

^d JOHNSON AND JOHNSON   (United States)

Author keywords

General practice; Primary care; Psoriasis; Referral patterns; UK

Indexed keywords

COLECALCIFEROL DERIVATIVE; CORTICOSTEROID; TAR; COLECALCIFEROL;

ADULT; ARTICLE; CASE CONTROL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; CORTICOSTEROID THERAPY; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PATIENT REFERRAL; PRIMARY MEDICAL CARE; PSORIASIS; RETROSPECTIVE STUDY; TOPICAL TREATMENT; UNITED KINGDOM; ADOLESCENT; AGED; ANALOGS AND DERIVATIVES; GENERAL PRACTICE; GREAT BRITAIN; MIDDLE AGED; RISK FACTOR; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CHOLECALCIFEROL; FAMILY PRACTICE; FEMALE; GREAT BRITAIN; HUMANS; INCIDENCE; LOGISTIC MODELS; MALE; MIDDLE AGED; PSORIASIS; REFERRAL AND CONSULTATION; RETROSPECTIVE STUDIES; RISK FACTORS; YOUNG ADULT;

EID: 84882987410     PISSN: None     EISSN: 14715945     Source Type: Journal    
DOI: 10.1186/1471-5945-13-9     Document Type: Article

References (25)

1. Greaves MW, Weinstein GD. Treatment of psoriasis. N Engl J Med 1995, 332:581-588. 10.1056/NEJM199503023320907, 7838193.
2. Conway P, Currie CJ. Descriptive epidemiology of hospitalisation for psoriasis. Curr Med Res Opin 2008, 24:3487-3491. 10.1185/03007990802583563, 19032130.
3. Gelfand JM, Weinstein R, Porter SB, Neimann AL, Berlin JA, Margolis DJ. Prevalence and treatment of psoriasis in the United Kingdom: a population-based study. Arch Dermatol 2005, 141:1537-1541. 10.1001/archderm.141.12.1537, 16365254.
4. Gelfand JM, Troxel AB, Lewis JD, et al. The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol 2007, 143:1493-1499. 10.1001/archderm.143.12.1493, 18086997.
5. Horn EJ, Fox KM, Patel V, et al. Association of patient-reported psoriasis severity with income and employment. J Am Acad Dermatol 2007, 57:963-971. 10.1016/j.jaad.2007.07.023, 17761358.
6. Rapp SR, Feldman SR, Exum ML, Fleischer AB, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999, 41:401-407. 10.1016/S0190-9622(99)70112-X, 10459113.
7. Duque MI, Yosipovitch G, Chan YH, Smith R, Levy P. Itch, pain, and burning sensation are common symptoms in mild to moderate chronic venous insufficiency with an impact on quality of life. J Am Acad Dermatol 2005, 53:504-508.
8. Husted JA, Tom BD, Schentag CT, Farewell VT, Gladman DD. Occurrence and correlates of fatigue in psoriatic arthritis. Ann Rheum Dis 2009, 68:1553-1558. 10.1136/ard.2008.098202, 18930991.
9. Chan B, Hales B, Shear N, et al. Work-related lost productivity and its economic impact on Canadian patients with moderate to severe psoriasis. J Cutan Med Surg 2009, 13:192-197.
10. National Health Services Psoriasis http://www.nhs.uk/Conditions/Psoriasis/Pages/NICE.aspx, National Health Services.
11. Smith CH, Anstey AV, Barker JN, et al. British association of dermatologists' guidelines for biologic interventions for psoriasis 2009. Br J Dermatol 2009, 161:987-1019. 10.1111/j.1365-2133.2009.09505.x, 19857207.
12. British National Formulary Edition 59 http://www.bnf.org, British National Formulary.
13. Huerta C, Rivero E, Rodriguez LA. Incidence and risk factors for psoriasis in the general population. Arch Dermatol 2007, 143:1559-1565. 10.1001/archderm.143.12.1559, 18087008.
14. The THIN database http://www.ucl.ac.uk/pcph/research-groups-themes/THIN-pub/databases/pros-cons.
15. Lewis JD, Schinnar R, Bilker WB, Wang X, Strom BL. Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research. Pharmacoepidemiol Drug Saf 2007, 16:393-401. 10.1002/pds.1335, 17066486.
16. Chisholm J. The Read clinical classification. Br Med J 1990, 300:1467.
17. Maguire A, Blak BT, Thompson M. The importance of defining periods of complete mortality reporting for research using automated data from primary care. Pharmacoepidemiol Drug Saf 2009, 18:76-83. 10.1002/pds.1688, 19065600.
18. Seminara NM, Abuabara K, Shin DB, et al. Validity of the health improvement network (THIN) for the study of psoriasis. Br J Dermatol 2011, 164:602-609. 3064479, 21073449.
19. Townsend Deprivation Index http://www.geog.soton.ac.uk/gen-refer/go3_142_c15p19819999snsw.html, Townsend Deprivation Index.
20. Edwards P, Robert I. Population adiposity and climate change. Int J Epidemiol 2009, 38:1137-1140. 10.1093/ije/dyp172, 19377099.
21. Gillard SE, Finlay AY. Current management of psoriasis in the United Kingdom: patterns of prescribing and resource use in primary care. Int J Clin Pract 2005, 59:1260-1267. 10.1111/j.1368-5031.2005.00680.x, 16236077.
22. Quality Outcomes Framework http://www.qof.ic.nhs.uk.
23. British Association of Dermatologists Treatment for moderate or severe psoriasis http://www.bad.org.uk/site/866/default.aspx, British Association of Dermatologists.
24. Langan SM, Seminara NM, Shin DB, et al. Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom. J Invest Dermatol 2011,
25. Griffiths CE, Clark CM, Chalmers RJ, Li Wan Po A, Williams HC. A systematic review of treatments for severe psoriasis. Health Technol Assess 2000, 4(1):1-25.